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In this issue of SQUMJ, Jafferbhoy et al. have shared their regional experience about the impact of adding positron emission 
tomography (PET)/computed tomography (CT) to 
conventional CT in the preoperative work-up and 
follow-up of a select group of patients with colorectal 
cancer.1 In their retrospective study, PET/CT had a 
major impact in the preoperative and follow-up groups, 
altering the management of 73% and 64% of cases, 
respectively. According to the authors, they selected 
colorectal cancer as the focus of their investigation 
as it is one of the most common cancers in the UK;1 
indeed, the survival rates of breast, colorectal and 
cervical cancer have more than doubled in the last 
six decades.2 The situation is similar in Oman, with 
colon cancer among the top 10 most common cancers 
for both genders.3 Therefore, the utilisation of PET/
CT for colorectal cancer patients in Oman may also 
lead to a change in management for the majority of 
these patients. 
In colorectal cancer, surgery is the potential curative 
treatment for localised disease in addition to chemo-
radiotherapy in selected cases. Salvage surgeries are 
usually performed for patients with recurrent disease 
and metastasectomies are an option for distant 
metastasis in some patients. In Oman, there is a lack of 
national screening programmes for common cancers 
such as breast, colorectal and prostate cancers; this may 
result in the late presentation of some cases. As such, 
it is very important to establish accurate preoperative 
staging of the disease. Furthermore, close monitoring 
and regular follow-up is essential in the postoperative 
period, as more than 85% of distant metastasis cases 
will appear within the first three years and all cases 
of metastasis in the first five years.4 Identifying cases 
of disease recurrence and managing them as early as 
possible improves the overall survival rate—it is at this 
point that PET/CT can play a significant role.3 PET/CT 
can not only aid in the early detection of recurrence 
but can also accurately determine recurrence when 
CT alone cannot identify the lesion, as shown by 
Jafferbhoy et al.1
In their study, Jafferbhoy et al. used 18F-fluoro-
deoxyglucose (18F-FDG)-PET/CT to evaluate patients 
preoperatively and during follow-up in order to detect 
early recurrence;1 this method is also recommended in 
the literature.5,6 The main indication for using PET/CT 
in this cohort was either as a problem-solving measure, 
in cases where conventional CT was equivocal or 
patients had rising carcinogenic embryonic antigen 
levels with negative CT results, or as a confirmatory 
tool, for patients who had resectable metastatic disease 
or evidence of disease recurrence on conventional CT. 
In the latter group, PET/CT was used to confirm the 
CT findings prior to surgery.1 In Oman, other state-
of-the-art modalities are used in the staging and 
follow-up of oncological patients, including 64-slice 
CT and 3Tesla magnetic resonance imaging machines, 
as well as trained and well-equipped surgical teams. 
Nevertheless, PET/CT can be a major contributor 
and aid in more effective utilisation of this expensive 
equipment and accompanying human resources. This 
technology will confirm findings in some cases as well 
as potentially identify recurrent disease that may be 
missed by other modalities. 
In an extensive review of all published randomised 
clinical trials and systematic reviews, Fletcher et 
al. proposed a number of recommendations for 
the utilisation of PET/CT in oncological patients.6 
Primarily, the authors recommended that 18F-FDG-
PET/CT be used for the diagnosis of lung, pancreas and 
head and neck cancers as well as cancers of unknown 
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primary. In addition, 18F-FDG-PET/CT should be 
utilised for staging breast, colon, oesophageal, lung, 
head and neck lymphomas and melanomas. Fletcher 
et al. also advocated that this modality be used for 
detecting the recurrence of colorectal, breast, head, 
neck and thyroid cancers and lymphomas.6 Apart from 
using PET/CT in staging, restaging and the evaluation 
of distant metastatic disease and local recurrence, it 
has a very important role in monitoring treatment. 
Traditionally, PET/CT has been used to assess the 
treatment response at the end of chemotherapy cycles 
as well as the overall response at the end of therapy.7 
However, more recent literature has shown that 
evaluating the response mid-treatment is useful to 
assess the response to that particular regime, as the 
waiting until the end of treatment to determine the 
patient’s response might be too late in some cases.8,9 
To this end, combined PET/CT can help in ensuring 
the cost-effective utilisation of expensive chemo-
therapy treatments. 
In their retrospective analysis of the cost-
effectiveness of mid-treatment PET/CT, Moulin-
Romsee et al. reported that performing PET/CT 
after three chemotherapy cycles in patients with non-
Hodgkin’s lymphoma saved an average of €1,879 per 
patient.10 Oman may potentially be an even better 
beneficiary than some European countries. Until a 
specific tumour-targeted therapy is readily available for 
oncologists and cancer patients in this country, PET/
CT is the best option. Further research has confirmed 
its efficiency in evaluating the early response to 
treatment—one such study noted that it could be used 
even as early as a week after a cycle of chemotherapy.11 
FDG-PET/CT is invaluable for more than just 
the above-described oncological indications. An 
interesting emerging application of FDG-PET is 
for thrombus imaging; this was initially discovered 
incidentally in aneurysms with thrombi.12 Another 
novel and fascinating aspect of FDG-PET/CT was 
discovered by Figueroa et al.; the imaging modality 
did not just predict the occurrence of cardiovascular 
disease (CVD) but also the potential timeframe of CVD 
events.13 In Oman, the incidence of CVD is the highest 
among all communicable and non-communicable 
diseases, with the proportional mortality due to CVD 
at 33%.14 In comparison, proportional mortality due 
to either diabetes or cancer were 10% each.14 Thus, 
introducing this modality in Oman will certainly have 
a considerable supplemental benefit to the health and 
welfare of Omani citizens—not only in the oncological 
context, but also in terms of the early detection of 
cardiac events and the reduction of cardiovascular-
related mortality.
Nonetheless, it is important to consider a few 
limitations to PET/CT imaging. As mentioned by Ben-
Haim et al., high blood glucose reduces the overall 
quality of PET/CT images.2 Abnormal lesions may 
therefore be missed in diabetics without controlled 
glucose levels. However, this problem may be overcome 
by using other non-FDG-PET/CT radiotracers (e.g. 
choline or methionine) which are not affected by high 
blood glucose levels. The other limitation of FDG-
PET/CT is the increased uptake of the tracer in cases 
of infection which can mimic that of tumours. While 
this can be considered a disadvantage of the modality, 
this feature of FDG-PET/CT has actually been utilised 
to image and evaluate patients with osteomyelitis, 
sarcoidosis and inflammatory bowel disease, where 
it showed high sensitivity in detecting the site of the 
lesions.15 It was also used for imaging purposes in 
patients with fever of unknown origin; due to the high 
affinity of FDG uptake at the sites of infection and 
inflammation, the modality was found to have a high 
sensitivity in detecting abnormalities.16
An additional limitation to the PET/CT 
modality, one which is probably unique to Oman, 
is its current non-availability within the country. 
Currently, only a small group of patients selected 
by a number of committees are able to benefit from 
PET/CT imaging abroad. So far it has been used as a 
problem-solving modality in cases where both other 
imaging modalities and tissue biopsies have proved 
inconclusive. Data analysis has clearly shown that the 
number of cancer patients in Oman is increasing, as 
it is globally.17 Thousands of potential patients would 
benefit from this service if it was made available in-
house. The fact that patients have to be sent abroad 
for PET/CT scans creates many logistic impediments 
as well as significantly underutilising one of the 
most effective and state-of-the-art modalities for 
oncological patients—not to mention the fact that it 
is uneconomical to send patients abroad to receive 
this service.17 
One of the fundamental human rights is the right 
to health. This necessarily involves the creation of a 
well-governed, financially secure, responsive and 
innovative health system that delivers services freely 
according to need.18 Unsurprisingly, we are currently 
facing an increase in the global incidence of cancer. 
According to the worldwide GLOBOCAN project, 
there were 14.1 million new cancer cases and 8.2 
million deaths due to cancer in 2012.19 Those numbers 
are expected to increase, with 22.2 million new cancer 
cases predicted for 2030.20 With such an immense 
surge in cancer patients expected within the next 
few decades, health services will face the significant 
challenge of coping with healthcare-related expenses. 
The optimisation and cost-effective utilisation of 
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available resources would be the most effective 
method to ensure the burden is not too great. This 
is particularly true for countries where healthcare is 
provided free to citizens by the government, such as 
in Oman. When it comes to managing oncological 
patients, PET/CT has proven without a doubt to 
be the leading modality. Over the last four decades, 
Oman has borne witness to vast improvements in 
health services with health providers continuing to 
pursue excellence; however, this excellence cannot be 
achieved without the establishment of a national PET/
CT service in Oman.
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